Evaluation of exacerbations and blood eosinophils in UK and US COPD populations

Respiratory Research
Claus F VogelmeierHui Cao

Abstract

Blood eosinophil counts and history of exacerbations have been proposed as predictors of patients with chronic obstructive pulmonary disease (COPD) who may benefit from triple therapy (inhaled corticosteroid, long-acting β2-agonist and long-acting muscarinic antagonist). In a retrospective cohort analysis we examined the profiles of COPD patients from the UK Clinical Practice Research Datalink (CPRD) and US Optum Clinformatics™ Data Mart (Optum) databases with reference to exacerbation frequency and blood eosinophil distribution. Of the 31,437 (CPRD) and 383,825 (Optum) patients with COPD, 15,364 (CPRD) and 139,465 (Optum) met the eligibility criteria and were included. Among patients with ≥2 exacerbations and available eosinophil counts in the baseline period (CPRD, n = 3089 and Optum, n = 13414), 17.0 and 13.3% respectively had eosinophil counts ≥400 cells/μL. Patients with ≥2 exacerbations or eosinophil count ≥400 cells/μL during first year, exacerbated at least once (CPRD, 82.8% vs Optum, 80.6%) or continued to have eosinophil count ≥300 cells/μL (76.8% vs 76.5%), respectively in the follow-up year. In both years, a higher variability in the number of exacerbations and eosinophil count was observed in patients with one exac...Continue Reading

References

Jan 25, 2008·The European Respiratory Journal·J VestboUNKNOWN ECLIPSE investigators
Mar 11, 2010·COPD·Elizabeth A ReganJames D Crapo
Mar 27, 2012·American Journal of Respiratory and Critical Care Medicine·Mona BafadhelChristopher E Brightling
Jun 29, 2013·Respiratory Medicine·Dendy MacaulayPaul F Simonelli
Mar 29, 2014·Respiratory Medicine·Jørgen VestboVictoria Higgins
Oct 18, 2014·The European Respiratory Journal·Dave SinghUNKNOWN ECLIPSE investigators
Jun 8, 2015·International Journal of Epidemiology·Emily HerrettLiam Smeeth
Dec 8, 2015·American Journal of Respiratory and Critical Care Medicine·Signe Vedel-KroghBørge G Nordestgaard
Sep 22, 2016·BMJ Open Respiratory Research·James L KreindlerNicholas Locantore
Feb 7, 2017·American Journal of Respiratory and Critical Care Medicine·Olorunfemi A OshagbemiFrits M E Franssen
Mar 10, 2017·American Journal of Respiratory and Critical Care Medicine·Nicolas RocheJadwiga A Wedzicha
Mar 18, 2017·American Journal of Respiratory and Critical Care Medicine·Peter M A CalverleyHenrik Watz
Feb 24, 2018·American Journal of Respiratory and Critical Care Medicine·Kieran J RothnieJennifer K Quint
Apr 19, 2018·The New England Journal of Medicine·David A LipsonUNKNOWN IMPACT Investigators
May 2, 2018·The Journal of Allergy and Clinical Immunology·Jeong H YunUNKNOWN COPDGene and ECLIPSE Investigators
Jul 14, 2018·Respiratory Research·Sun Hye ShinUNKNOWN KOLD Study Group

❮ Previous
Next ❯

Citations

Dec 20, 2019·Postgraduate Medicine·G HillasA I Papaioannou
Apr 24, 2020·Respiratory Research·Alexander J MackayJadwiga A Wedzicha
Jun 26, 2020·Thorax·Hannah Whittaker, Jennifer K Quint
Jan 21, 2020·Expert Opinion on Pharmacotherapy·Timothy E AlbertsonSusan Murin
Nov 6, 2020·International Journal of Chronic Obstructive Pulmonary Disease·Andriana I PapaioannouNikos Tzanakis
Mar 17, 2021·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Konstantinos KostikasStelios Loukides
Mar 30, 2021·International Journal of Chronic Obstructive Pulmonary Disease·Kjell LarssonLeif Jorgensen
May 21, 2021·International Journal of Chronic Obstructive Pulmonary Disease·Ioanna TsiligianniRudi Peché
Sep 2, 2021·International Journal of Chronic Obstructive Pulmonary Disease·Claus F VogelmeierFelix W Friedrich

❮ Previous
Next ❯

Software Mentioned

ECLIPSE
IMPACT
OPTUM
COPDGene

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.